标准治疗用西达基奥仑赛治疗复发/难治性多发性骨髓瘤的安全性与疗效
报告2022年3月1日至12月31日在美国16家学术医学中心接受白细胞分离术制备西达基奥仑赛的复发/难治性多发性骨髓瘤患者结局:255例接受白细胞分离术,236例(92.5%)接受治疗,其中54%不符合CARTITUDE-1入选标准;细胞因子释放综合征75%、总缓解率89%、12个月无进展生存估计68%,非复发死亡10%。
要点
- 236例接受西达基奥仑赛治疗者细胞因子释放综合征75%(≥3级5%),免疫效应细胞相关神经毒性综合征14%(≥3级4%)。
- 全部治疗者总缓解率89%、完全缓解率70%;符合产品规范者(n=191)分别为94%和74%。
- 中位随访13个月,中位无进展生存未达到,12个月无进展生存估计68%(95%CI 62-74)。
核心结论
- 在复发/难治性多发性骨髓瘤中,标准治疗用西达基奥仑赛观察到有利的疗效特征,尽管超过半数患者不符合CARTITUDE-1入选标准。
研究设计与样本
- 多中心队列研究,纳入2022年3月1日至2022年12月31日在美国16家学术医学中心为制备西达基奥仑赛接受白细胞分离术的复发/难治性多发性骨髓瘤患者。
- 255例接受白细胞分离术,236例(92.5%)接受西达基奥仑赛治疗,其中54%不符合CARTITUDE-1入选标准。
主要发现
- 治疗患者(N=236)中细胞因子释放综合征发生率为75%(≥3级5%),免疫效应细胞相关神经毒性综合征14%(≥3级4%),迟发性神经毒性10%。
- 全部治疗患者(N=236)总缓解率89%、完全缓解率70%;接受符合规范产品者(n=191)分别为94%和74%;符合规范产品且使用氟达拉滨/环磷酰胺淋巴细胞清除者(n=152)分别为95%和76%。
- 非复发死亡率为10%,最常见原因为感染。
- 自西达基奥仑赛输注起中位随访13个月,中位无进展生存未达到,12个月无进展生存估计为68%(95%CI 62-74)。
- 高铁蛋白水平、高危细胞遗传学和髓外疾病与较差的无进展生存独立相关,既往B细胞成熟抗原靶向治疗有相关信号(P=.08);排除非黑色素瘤皮肤癌的第二原发恶性肿瘤为5.5%,髓系恶性肿瘤/急性白血病为1.7%。
关键数值与推荐
- 全部接受西达基奥仑赛治疗患者(N=236)总缓解率89%、完全缓解率70%。
- 接受符合规范西达基奥仑赛者(n=191)总缓解率94%、完全缓解率74%。
- 符合规范西达基奥仑赛联合氟达拉滨/环磷酰胺淋巴细胞清除者(n=152)总缓解率95%、完全缓解率76%。
- 12个月无进展生存估计68%(95%CI 62-74)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 1 March 2022 and 31 December 2022 at 16 US academic medical centers were included. Overall, 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel, of which 54% would not have met CARTITUDE-1 eligibility criteria. In treated patients (N = 236), cytokine release syndrome was seen in 75% (grade ≥3, 5%), immune effector cell-associated neurotoxicity syndrome in 14% (grade ≥3, 4%), and delayed neurotoxicity in 10%. Overall and complete response rates were as follows: all patients who received cilta-cel (N = 236), 89% and 70%; patients receiving conforming cilta-cel (n = 191), 94% and 74%; and conforming cilta-cel with fludarabine/cyclophosphamide lymphodepletion (n = 152), 95% and 76%, respectively. Nonrelapse mortality was 10%, most commonly from infection. After a median follow-up of 13 months from cilta-cel, the median progression-free survival (PFS) was not reached, with 12-month estimate being 68% (95% confidence interval, 62-74). High ferritin levels, high-risk cytogenetics, and extramedullary disease were independently associated with inferior PFS, with a signal for prior B-cell maturation antigen-targeted therapy (P = .08). Second primary malignancies excluding nonmelanoma skin cancers were seen in 5.5% and myeloid malignancies/acute leukemia in 1.7%. We observed a favorable efficacy profile of standard-of-care cilta-cel in RRMM, despite more than half the patients not meeting the CARTITUDE-1 eligibility criteria.
引用
- Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025. PMID: 39365257. doi:10.1182/blood.2024025945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。